INTRODUCTION
The prevalence of several diseases has changed with the advent of human immunodeficiency virus (HIV) pandemic. The incidence and prevalence of some infectious diseases that were hitherto on the decline are now experiencing an upward trend1-5. Hepatitis B (HBV) is a very important potentially lethal and presently treatable disease. This on its own may be a 5 significant cause of morbidity and mortality. The prevalence rate of HBV infection has been shown to be higher in HIV infected 6, 7 persons than the general population . The presence of hepatitis B in HIV infected patients may pose serious problems for them.
The prevalence of HBV varies significantly from one geographical region to another. It is highly endemic in south East Asia, China and Sub-Saharan Africa with 7 carrier rates of 8-20 percent. In these regions 70-90% of the population show serologic evidence of previous and current HBV infection. In the general population, the prevalence is between 0.5-2 percent. In Nigerian children, a prevalence of 10% has 7 been reported . Amongst Intravenous (IV) drugs users and HIV infected persons the 5 prevalence is higher .
Transmission of HBV and HIV infection is quite similar. Both infections are transmitted horizontally and vertically. Horizontally, transmission occurs via coitus, percutaneous and parenteral routes such as transfusion of contaminated blood or blood products, needlestick injuries, intravenous (I.V) drug abuse, dental and surgical procedures, hemodialysis, tattooing, acupuncture, circumcision and ear piercing. Vertical transmission occurs from infected mother to infants in the uterus or during the 7, 8 perinatal or postnatal period.
The incubation period of this infection averages about 3 months, with a transient viraemia lasting 4-8 weeks. In about 90% of patients, the acute infection is silent. The three antigens hepatitis B surface antigen (HbsAg), hepatitis B core antigen (HbcAg) and Hepatitis B infectivity antigen (HbeAg) 8 elicit an antibody response . Only Anti-HBS 7, 8 Alaska to 30-98 in the Far East.
HIV infection has reached pandemic proportions worldwide with sub Saharan Africa being the worst hit. In Eastern and southern Africa the prevalence ranges from 9 9% in males to 34% in females . Whilst in 10 Nigeria, the prevalence is 4.4% . It is caused by a retrovirus that attacks the central point in the human immune system, the CD4+ cell, and therefore lowers the patient's, immunity and predisposes the patient to opportunistic 11, 12 infections and secondary malignancies .
There is an acute phase of infection which in most cases is silent but about 20% present with flu-like symptoms and a glandular fever like illness, sometimes aseptic meningitis (stage 1). The infection becomes latent and asymptomatic for 5-8 years (stage II). Then it gets to the stage where in about 10% of patients there is persistent generalized lymphadenopathy (stage III) and finally AIDS develops(stage IV) with full blown symptoms such as wasting (slim disease) recurrent fever and diarrhoea, numerous skin manifestations, opportunistic 12 diseases and secondary malignancies . Highly active antiretroviral therapy (HAART) is giving HIV infected patients a new lease of life, therefore, there is need to tackle the health problems associated with HBV in order to reduce the morbidity and mortality in these patients. Also with the use of lamivudine as treatment in patients infected with HBV, the outlook is improving for HIV and HBV co-infected patients.
Studies have been done in Nigeria to determine the prevalence of HBV in the general population especially amongst certain risk groups such as Health workers, Blood donors, dialysis patients and prisoners, but no study has been done amongst HIV infected persons, comparing the findings with controls in this part of the country. The paucity of reports from this region warrants a closer study of these diseases in this environment. Therefore the objective of this study is to determine the seroprevalence of Hepatitis B infection amongst HIV infected persons in Edo state, Nigeria. Using a prevalence of 6.05% , sample size for 13 comparative study per group was 93. However a sample size of 204 patients HIV positive and 166 controls was used.
PATIENTS AND METHODS

Patients
Laboratory Methods
Two assays were done for each of the patients: HIV screening by Elisa technique and confirmed by double Elisa and Hepatitis B virus (HbsAg) screening.
Hiv Test
The tests for HIV were done using ELISA HIV test kits, Determine by Abbott and Stat Pak by CHEMBIO. Confirmation of indeterminate cases was done with GENIE by BIO-RAD.
HbsAg test
The screening tests for HbsAg were done using the ELISA test kits by Human Gesellschaft for biomedical and diagnostica m b t i -m b h m a x -p a n c h -i n g 2 1 -6 5 2 0 5 Wiesbauden Germany. Fasting blood sugar and Hemoglobin electrophoresis were done to rule out diabetes mellitus and sickle cell anemia respectively. Routine full blood counts, electrolytes and urea and liver function tests were also done.
Statistics
The data were analyzed using the EPI-INFO 6 statistical program. Continuous variables w e r e d e s c r i b e d w i t h m e a n s w h i l e discontinuous variables were described with proportions. Group means were compared with two-tailed t-test. When comparing 2 groups of subjects, the X (Chi square) test was applied to determine the significance of differences observed. Where the number in any cell was less than five, Fisher exact tests were used.
Results
A total of 370 subjects were involved in the study. There were 204 HIV positive patients while another 166 were HIV negative controls .Amongst the HIV positive patients, 81 were males and 123 were females with a mean age of 37.14 +10.94years (Age range 15-70years) In the control group 66 were males and 100 were females with a mean age of 37.21+ 11.30 years (Age range 15-70 years). There was no significant age and sex difference between HIV positive patients and controls.(P>0.05). Table 1 shows that the two groups of patients in the study were comparable as regards age and sex. Table 2 : shows the clinical stage I -II of HIV infected patients seen in this study. A total of 145 (71%) were asymptomatic. Fifty-six (56) were male while 89 were female. Two subjects, both male (1.0%) had only persistent generalized lymphadenopathy. Fifty-seven (57) patients (27%) had full blown AIDS; twenty-three (23) who were males while 34 were female. Table 3 : shows the prevalence of hepatitis B and HIV co-infection compared to the HIV negative controls. Of the 204 HIV infected patients tested, 22(10.8%) were also hepatitis B infected compared to 12 (7.2%) out of the 166 HIV negative controls. Even through the prevalence of hepatitis B infection is higher in HIV infected patients, this difference is, however, not statistically significant from that in HIV negative controls (P>0.05). The overall prevalence of Hepatitis B infection in both groups was 9.2%.
Discussion
HIV disease affects the prevalence and prognosis of HIV infection. In the developed world, the prevalence of HBV infection in the general population is 0.5-2% but is up to 80 in a teaching hospital in Jos . In sub Saharan Africa carrier rates are 8.2% in published data 19, 20 .The prevalence in this study is therefore comparable with other reports, despite the difference between the prevalence in HIV positive and HIV negative patients that is not 2 statistically significant (X =0.99). Report in 16 Nigeria by Idoko and Sirisena showed a significant difference between the HIV positive and HIV negative groups in Nigeria. This difference is more pronounced in data 5 from developed countries .
The observed lower prevalence of hepatitis B in this study as compared with 5, 16 some other rates in the literature may be due to the sample size used compared to other studies. It may be due to lower prevalence of risk factors for HBV transmission in this study group such as Intravenous drug users 5 (IDUS), blood products recipients, and 18 hemodialysis patients . The prevalence of HBV in HIV patients in this study though not significantly higher in HIV infected individuals than controls was lower compared to figures reported in Europe and 5 America . In these counties, HIV and HBV coinfection was usually associated with I.V. drugs abuse, which in itself is a major risk factor for HBV transmission. Intravenous drug abuse is not a common problem in this part of the world and is still not a major route for HIV transmission in Africa. A more prevalent risk factor such as homosexuality in the western world is also a risk factor, which is not as frequently reported in this 5 part of the world . This may explain the comparatively low figures seen in this study.
Other studies focus on the prevalence of HBV in high risk groups such as commercial sex workers, intravenous drug users, blood products recipients and blood donors. This study was conducted amongst patients who largely did not have these risk 20, 21 factors .
The prevalence reported in this study of HBV in HIV patients actually compares with that in the general population as seen in this study. This is in agreement with other studies done both in Nigeria and elsewhere showing that HIV prevalence did not on its own affect the HBV prevalence in this part of the world. The study done in Jos, Nigeria, which showed significant differences were done among prisoners who are a high risk group for homosexual behavior and I.V drug abuse, and among hemodialysis patients who on their own are a high risk group for HBV 16-,18 infection. .
The prevalence of Hepatitis B is not significantly higher in HIV positive individuals than in the general population in © CMS UNIBEN JMBR 2007 EDITION; VOL 6 (1& 2) this study. It is important to note however that the prevalence of hepatitis B in the general population is also quite high. This highlights the need for prevention of this disease. Thus all blood for transfusion should be screened for these infections and standard infection control measures (universal and standard precautions) should be emphasized in all levels of population and especially among healthcare workers in our hospitals.
